BSS Pharmaceutical Holding acquired two medical device distributors

The holding explained that the acquired companies are planned to be used to commercialize products from the Endoart plant (part of BSS). The plant has been engaged in the mass production of endoprostheses since September 2024. The total investment in this project during the first stage amounted to over 1 billion rubles, financed by the company's own funds. Currently, the first production line has a capacity of 35,000 hip endoprosthesis kits per year.

BSS reported that in 2026, the plant plans to expand its product line by adding revision systems for hip replacement, new models of endoprosthesis stems with a bioactive coating, and the first domestically produced knee endoprosthesis.

Medimpuls and Simplant will handle logistics, maintenance, and repair of medical equipment. For example, Simplant specialists will focus on repairing power orthopedic equipment and equipping it with Russian-made blades, ensuring the smooth operation of operating rooms. According to BSS Holding, Medimpuls will help expand the product range with endoprostheses manufactured by Endoart. Participation in the development of the holding's product strategy is also among the responsibilities.

According to SPARK-Interfax, Medimpuls LLC was registered in St. Petersburg in 2008. The company's revenue last year amounted to 1.48 billion rubles, with net profit of 177 million rubles. Edifarm has owned 100% of the shares since September 26, 2025. Simplant LLC has been operating in St. Petersburg since 2005. Changes to the ownership structure were also made on September 26. Revenue in 2024 amounted to 606 million rubles, with net profit of 93.3 million rubles.

According to SPARK-Interfax, BSS LLC is 100% owned by Eduard Zakhrabekov. In 2024, the holding company generated revenue of 68.8 billion rubles, with net profit of 2 billion rubles.

The BSS Holding was founded in St. Petersburg in 1996. It currently comprises 15 branches and 76 representative offices. The holding includes an essential oil company under the Aspera brand, the Dr. Pel Family Clinic, a chain of veterinary clinics, the Endoart implant manufacturing plant, and the IT company Zen IT. The holding's retail division also includes 616 pharmacies under the Aloe brand. This chain, with revenue of 19.373 billion rubles as of the end of 2024, ranked 18th in the Vademecum Analytical Center's "TOP 200 Pharmacy Chains in Russia" ranking. In mid-July 2024, BSS acquired the Murmansk company Murmansk Pharmacia, which owns 40 branches and specializes in retail sales of medications through pharmacies.

Over the past few years, BSS has been actively expanding its various business lines. In 2020, for example, BSS-Cosmetics (distributing products for aesthetic medicine and cosmetology) and BSS-Estetika (supplying implants and post-operative garments) were established. Furthermore, the holding company announced the creation of BSS-Lab, which supplies reagents for laboratory research in the fields of immunochemistry, biochemistry, hematology, hemostasis, and urinalysis, as well as supplies for microbiology laboratories.

In 2021, Eduard Zakhrabek became a 60% owner of BSS Food LLC, announcing his intention to begin supplying baby and therapeutic nutrition, including specialized nutrition for young children and those with specific medical conditions.